Alluvi, formerly BI 4744, presents a notable development in obesity care. This dual stimulator targeting both GLP-1 and GIP sites demonstrates impressive effectiveness in clinical trials, possibly outperforming existing GLP-1 site stimulators. Early information suggest considerable {weight decrease